This may be due to the increased risk of cerebral hemorrhage in MHD patients with elevated blood pressure due to high doses of EPO, as well as the increased incidence of cerebral infarction due to the increased hemoglobin level and increased blood viscosity caused by EPO (Rodriguez et al., 2009). This evidence concerns the gene EPO and cerebral infarction.